Cristobal Morales1, Virginia Bellido2, Cristina Tejera3, Fernando Goñi4, Rafael Palomares5, Cristina Sevillano6, Diego Bellido7, Alfonso Soto8, Miguel Ángel Mangas9, Manuel A Botana10, Irene Caballero1. 1. Departamento de endocrinología y Nutrición, Hospital Universitario Virgen Macarena, Seville, Spain. 2. Departamento de endocrinología y Nutrición, Hospital Universitario de Cruces, Bilbao, Spain. 3. Departamento de endocrinología y Nutrición, Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain. 4. Departamento de endocrinología y Nutrición, Hospital de Basurto, Bilbao, Spain. 5. Departamento de endocrinología y Nutrición, Hospital Reina Sofía de Córdoba, Cordoba, Spain. 6. Departamento de endocrinología y Nutrición, Hospital Intanta Leonor de Madrid, Madrid, Spain. 7. Departamento de endocrinología y Nutrición, Clínica Privada ENDOFER, La Coruña, Spain. 8. Departamento de endocrinología y Nutrición, Complejo Hospitalario Universitario de A Coruña, La Coruña, Spain. 9. Departamento de endocrinología y Nutrición, Hospital Universitario Virgen del Rocio de Sevilla, Seville, Spain. 10. Departamento de endocrinología y Nutrición, Hospital Universitario Lucus Augusti de Lugo, Lugo, Spain.
Abstract
Background: Weight reduction and glycemic control are key goals during Type 2 diabetes management. However, there are few country-specific, real-world data on cotransporter 2 inhibitors. Materials & methods: DAPA-RWE was a retrospective, multicenter study comparing the efficacy of dapagliflozin versus sitagliptin in Type 2 diabetes patients in Spain. Results: The study population comprised 1046 patients (594 with dapagliflozin, 452 with sitagliptin). Age was 61.8 ± 10.0 and 66.2 ± 11.4 years and glycosylated hemoglobin (HbA1c) 8.9 and 8.8%, respectively. The main end point (reduction in weight and HbA1c) was reached by 24.4 and 56.1% of patients, respectively; p < 0.05. This was confirmed with a propensity score matching analysis balanced for obesity-related variables at baseline. Conclusion: DAPA-RWE confirmed dapagliflozin to be more effective than sitagliptin in reducing HbA1c and weight.
Background: Weight reduction and glycemic control are key goals during Type 2 diabetes management. However, there are few country-specific, real-world data on cotransporter 2 inhibitors. Materials & methods: DAPA-RWE was a retrospective, multicenter study comparing the efficacy of dapagliflozin versus sitagliptin in Type 2 diabetespatients in Spain. Results: The study population comprised 1046 patients (594 with dapagliflozin, 452 with sitagliptin). Age was 61.8 ± 10.0 and 66.2 ± 11.4 years and glycosylated hemoglobin (HbA1c) 8.9 and 8.8%, respectively. The main end point (reduction in weight and HbA1c) was reached by 24.4 and 56.1% of patients, respectively; p < 0.05. This was confirmed with a propensity score matching analysis balanced for obesity-related variables at baseline. Conclusion:DAPA-RWE confirmed dapagliflozin to be more effective than sitagliptin in reducing HbA1c and weight.
Authors: Cristóbal Morales; Juan Francisco Merino-Torres; Paloma Moreno-Moreno; María Lainez; Iñigo Tejado; Alfredo Yoldi; Sonsoles Gutiérrez Medina; Alfonso Soto; Manuel A Botana; Virginia Bellido; Irene Caballero Journal: Drugs Context Date: 2022-02-17